Payment & Shipping Terms:
|CAS:||334618-23-4||Usage:||Linagliptin Intermediate Alogliptin Intermediate Trelagliptin|
|Molecular Formula:||C5H12N2 . 2HCl||Molecular Formula -:||C5H14Cl2N2|
51019 43 3,
334618 23 4
CAS : 334618-23-4 Linagliptin Intermediate ( R ) - 3 - aminopiperidine dihydrochloride
Chemical Name : ( R ) - 3 - aminopiperidine dihydrochloride
CAS No . : 334618-23-4
Synonyms : ( R ) - 3 - aminopiperidine 2HCl ; ( R ) - 3 - Piperidinamine dihydrochloride ; ( R ) - 3 - Piperidinamine 2HCl
Molecular Formula : C5H12N2 . 2HCl ; C5H14Cl2N2
Molecular Weight : 173.08
Usage : Linagliptin Intermediate ; Alogliptin Intermediate ; Trelagliptin Intermediate
Description : Linagliptin is the active pharmaceutical ingredient (API) of branded drug Tradjenta, Trajenta or Trazenta. It was innovated by the Germany drug maker Boehringer Ingelheim and cooperated the marketing with Lily. Linagliptin was approve by the US FDA in 2011. Linagliptin is used for the treatment of type 2 diabetes. Linagliptinis is a Dipeptidyl peptidase-4 inhibitor (DPP-4, DPP-IV).
( R ) - 3 - aminopiperidine dihydrochloride CAS No . : 334618-23-4 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our products are for R&D purpose. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.